The preceding measles rash may be subtle or absent in an immunocompromised host
are particularly at risk of PV-B19 infection, including patients with congenital or acquired immune deficiency, acquired immunodeficiency syndrome (AIDS) and cancer, and in transplant patients on immunosuppressive treatment.
These findings indicate that E bieneusi may disseminate and represent a common cause of peritonitis of unknown origin in the immunocompromised host
microti infection in highly immunocompromised hosts
The emergence of resistant organisms as a cause of serious infection in the immunocompromised host
requires a reexamination of our infection control practices.
To the Editor: Extrapulmonary involvement of tuberculosis increases with the rise of the incidence of immunocompromised host
, especially in acquired immunodeficiency syndrome, and it can occur even in immunocompetent patients.
Trichodysplasia spinulosa newly described folliculocentric viral infection in an immunocompromised host
2) Such a designation clarifies that these infections are not rare illnesses restricted to esoteric corners of medical practice, but rather, relatively common infections in a previously rare but now routinely encountered organism-the immunocompromised host
Chanock's laboratory is in the Immunocompromised Host
Section, Pediatric Oncology Branch, at the Advanced Technology Center of the National Cancer Institute.
As previously reported, a retrospective review of data from open label clinical trials, presented at the 1996 Symposium on Infections in the Immunocompromised Host
, showed an overall response rate to AMPHOTEC of 53 percent in 99 patients with well-documented fungal infections who received a minimum of seven days of treatment.
The case suggests that, even without an identifiable immunocompromised condition, a patient with LYG should be considered an immunocompromised host
, and rituximab or other immunosuppressive treatments should be prescribed cautiously; the possibility for rare complications should be recognized.
Thomas Walsh, chief, Immunocompromised Host
Section, National Cancer Institute, Bethesda, MD.